DNMT3A mutation + FLT3-ITD mutation
|
AML
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
cytarabine Resistant: C3 – Early Trials
|
cytarabine Resistant: C3 – Early Trials
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
gilteritinib Sensitive: C3 – Early Trials
|
gilteritinib Sensitive: C3 – Early Trials
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
quizartinib Sensitive: C3 – Early Trials
|
quizartinib Sensitive: C3 – Early Trials
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
DNMT3A mutation + FLT3-ITD mutation
|
AML
|
venetoclax Sensitive: C4 – Case Studies
|
venetoclax Sensitive: C4 – Case Studies
|